Abstract: The present invention provides methods for treating Alzheimer's Disease, or preventing synaptic death associated with Alzheimer's Disease by administering a Pyk2 inhibitor. In certain embodiments, the Pyk2 inhibitor is specific for Pyk2. In other embodiments, the Pyk2 inhibitor also inhibits Fyn.

Abstract: The present invention provides compounds of the formula below pharmaceutically acceptable salts of the compounds, methods of treating patients for liver disease, and processes for preparing the compounds.

Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.

Abstract: A solid dispersion of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the solid dispersion are provided herein. Also, a pharmaceutical composition comprising a solid dispersion of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and uses thereof are provided herein.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating macular degeneration containing trametinib or gefitinib, and to a method of screening a therapeutic agent for macular degeneration. The pharmaceutical composition of the present invention is capable of inhibiting the phosphorylation of keratin 8 and the reorganization thereof around nuclei in retinal pigment epithelial cells under oxidative stress conditions, increasing the expression of E-cadherin, and reducing the expression of vimentin, and can thus be efficiently useful for the prevention or treatment of macular degeneration.

Abstract: Disclosed are oral pharmaceutical compositions of neflamapimod that exhibit suitable exposure for administration in humans and/or that maintain a desirable dissolution profile under standard storage conditions.

Abstract: The invention relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) and inhibitors of Neprilysin (NEP) useful for the treatment of certain cardiovascular diseases or related disorders, e.g., hypertension, congestive heart disease, and post-myocardial infarction. In another embodiment, the invention relates to the combination of inhibitors of PDE1 and inhibitors of NEP for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP/PKG mediated pathways in the cardiovascular system (e.g., in cardiac tissue or in arterial smooth muscle).

Abstract: The invention relates to therapeutic applications for compositions that reduce the level of oxidative stress on cells in vivo or in vitro. The invention describes methods for improving the therapeutic properties of stem cells. The invention also provides combination therapies that are useful to balance the oxidative microenvironment of cells in vivo or in vitro.

Abstract: Methods for treating insomnia are disclosed. The methods are directed to administering a pharmaceutically effective amount of phosphodiesterase 5 (PDE5) inhibitor to a male individual suffering from insomnia. In addition, due to the PDE5 inhibitor positive effects on addressing erectile dysfunction (ED) in males, the present methods are directed to treating insomnia in patients that also suffer from ED by administering a pharmaceutically effective amount of a PDE5 inhibitor.

Abstract: This invention relates to a method of treating non-small cell lung cancer by administering an EGFR T790M inhibitor in combination with a CDK inhibitor to a patient in need thereof.

Abstract: It is found that a nucleoside derivative represented by the following general formula (1) has an anti-viral activity and is less toxic to host cells. [in the formula, R1 represents a hydrogen or halogen atom, R2 represents a hydrogen or halogen atom, R3 represents a cyano group, an alkyl group which may have a substituent, an alkenyl group which may have a substituent, an alkynyl group which may have a substituent, a halogen atom, or an azido group, R4 represents an amino group, a hydrogen atom, a halogen atom, or a hydroxy group, R5 represents a nitrogen atom or a methine group, R6 represents a hydrogen atom or a hydroxy group, and R7 represents a hydrogen atom or a hydroxy group.

Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract: The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of an HBV capsid assembly inhibitor and a nucleoside or nucleotide analogue for use in the treatment or prophylaxis of chronic hepatitis B patient.

Abstract: The present disclosure relates to administration of meloxicam intravenously, for treatment of pain, in patients who are at least 65 years old and have mild renal impairment, which can provide fast onset of pain relief suitable for management of acute pain as well as moderate to severe pain.

Abstract: The present disclosure relates to meloxicam bolus formulations and methods of administering the same intravenously, for treatment of pain, which can provide fast onset of pain relief suitable for management of acute moderate to severe pain.

Abstract: The present invention relates to methods for weight management that utilize modified-release dosage forms comprising (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts and crystalline forms thereof. The present invention further relates to (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts, crystalline forms thereof and modified-release dosage forms comprising them.

Abstract: Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.

Abstract: In various embodiments, the present disclosure provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof having triglyceride levels of about 200 mg/dL to about 499 mg/dL, diabetes mellitus, and reduced kidney function.

Abstract: The present invention is directed to compositions and methods for treating addiction and/or substance use disorders, including nicotine addiction associated with smoking tobacco. In particular, this invention is directed to combinations of low doses of a cortisol synthesis inhibitor, such as metyrapone, in combination with low doses of a benzodiazepine, such as oxazepam. The compositions and methods of the present invention include pharmaceutical compositions and methods that are safe and efficacious for treating animals and humans.

Abstract: The group of inventions relates to medicine, pharmacology, namely to psychiatry and can be used for effective and safe treatment of mental disorders associated with dysfunction of dopamine and serotonin (5-hydroxytryptamine) neurotransmitter systems. Pharmaceutical compositions containing halogenated clozapine, in an amount effective as selective antagonists of D4 and 5NT2A receptors, and at least one pharmaceutically acceptable carrier, as well as their use and methods of treatment are offered for this purpose. The inventions make it possible to create a new drug with a well-balanced receptor profile, the intake of which will allow to treat mental disorders in an effective way without causing side effects associated with exposure to receptors that are not involved in the pathology of a mental disorder.

Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.

Abstract: The invention relates to inhibiting the development of hepatic fibrosis in a human subject afflicted with Non-Alcoholic Fatty Liver Disease and having a fibrosis score of zero comprising administering to the subject greater that 300 mg per day of 3?-arachidylamido-7?, 12?-dihydroxy-5?-cholan-24-oic acid (Aramchol), or a pharmaceutically acceptable salt thereof, thereby inhibiting the development of hepatic fibrosis in said subject.

Abstract: Device and method for improving the effectiveness of osteopathic pain therapy by monitoring one or more pharmacokinetic parameters of the subject with a point-of-care device after pain drug administration. In one embodiment, the pain drug is celecoxib and the pharmacokinetic parameter is AUC.

Abstract: Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

Abstract: Disclosed are prodrugs of anthracyclines (such as doxorubicin) and derivatives thereof that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of “warhead” anthracycline or anthracycline derivative to FAP-expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, undesirable fibrosis, and undesirable inflammation.

Abstract: A method for improving ventilatory efficiency, comprising the administration of a pentose is disclosed. The most preferred pentose is D-ribose, to be administered in a dosage of from two to ten grams, one to four times daily for at least a week, but most preferably long term.

Abstract: A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.

Abstract: The present invention is directed to methods for treating ebola virus infections or Marburg virus infections comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to the therapeutic use of acylated piceid derivative compounds in ocular pathologies, in particular retinitis pigmentosa and in age-related macular degeneration.

Abstract: The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase and at least one active phase comprising at least one active compound chosen from avermectin compounds and at least one solvent and/or propenetrating agent of avermectin compounds, where the composition comprises less than 3% by weight of solid fatty substances at room temperature and at atmospheric pressure, relative to the total weight of the composition. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.

Abstract: Methods for ameliorating cardiac is juries such as myocardial infarction by either enhancing the activity of a let-7 microRNA or inhibiting the activity of transformation growth factor beta receptor III (T GFBR3). Also provided herein are assay methods for detecting the level of TGFBR3, the level of a let-7 microRNA, or both in a biological sample.

Abstract: A composition for delivering a biologic to a subject generally includes a particulate substrate and an mRNA encapsulated by the particulate substrate. In some cases, the mRNA bay be indirectly attached to the particulate substrate. The mRNA encodes at least one therapeutic polypeptide. The composition may be delivered to a tissue of a subject to provide a therapeutic benefit to the tissue.

Abstract: Provided herein are pharmaceutical compositions comprising Eteplirsen. Also provided herein are methods of treating a muscle disease in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of the disclosure.

Abstract: The invention relates to virucidal compounds, virucidal compositions comprising thereof and uses thereof in treatment of viral infections, for sterilizations and for disinfections.

Abstract: The present disclosure relates to use of heparin analogues as inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.

Abstract: Provided in the present invention is a composition having a novel use and containing a neoagarooligosaccharide mixture as an active ingredient. According to the present invention, a neoagarooligosaccharide mixture, which is the active ingredient of the composition according to the present invention, and the like can reduce the expression of RANKL, which is an osteoclast inducer, and effectively inhibit the differentiation of mononuclear cells into osteoclasts. Therefore, the composition according to the present invention can be used as a medicine or functional food for preventing, alleviating, or treating arthritis (especially rheumatoid arthritis) or osteoporosis.

Abstract: The present invention relates to dietary fiber compositions that can provide an increased level of acetate in the distal colon. Increase levels of acetate (or other short chain fatty acids; SCFA's) in the distal part of the colon is believed to be beneficial in the treatment of various diseases or conditions, such as being overweight or obese. To accomplish this using dietary intervention, which is clearly the preferred (first-line) option for the treatment and/or prevention of obesity (and related disorders), has been a challenge. It was now surprisingly found that combinations of an inulin-type fructan and resistant starch can be orally consumed to substantially increase the level of acetate in the distal part of the colon in human subjects.

Abstract: A sanitizing formulation is disclosed for use as a hand sanitizer. The formulation may include hypochlorous acid, a silicone polymer or blend thereof, sodium phosphate, hydrochloric acid, and sodium magnesium silicate. Methods of using and making the sanitizing formulation are also disclosed.

Abstract: Compositions for the treatment of microbial infections and for the general well-being of a mammals' skin, nails, hooves, claws and/or feet, including a blend of copper sulfate, water, and at least one clay or clay-like material, methods for making such compositions, and methods for the use of such compositions to control, treat, prevent microbial infections of the same.

Abstract: The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

Abstract: Methods of tissue grafting, and more particularly methods for enhancing tissue graft revascularization, e.g., host engagement of pre-existing graft blood vessels.

Abstract: Provided are recombinant polynucleotides, including expression vectors encoding an alpha chain and/or a beta chain of a TCR having amino acid sequences from any of novel the AL, KQ, PP, 19305CD8, BB, KB, ST, JD, 19305DP, PB-P, PB-T, and PB 13.2 T Cell Receptors (TCRs) that are embodiments of the invention. Cells comprising the polynucleotides are provided, as are libraries of the recombinant polynucleotides and expression vectors. Methods are provided and involve administering to an individual modified human T cells that express a novel recombinant TCR. The methods are for prophylaxis and/or therapy of an individual diagnosed with, suspected of having or at risk for developing or recurrence of a cancer, wherein the cancer includes cancer cells which express NY-ESO-1 and/or its highly homologous LAGE-1 antigen.

Abstract: The present invention provides compositions, devices, and methods for the coordinated delivery of transplant material and immune suppressors for control of transplant rejection. In particular embodiments, immune suppression cells (e.g., regulatory T cells) and transplant material (e.g., cells, tissue, etc.) are provided within a delivery scaffold for transplant into a subject.

Abstract: The present disclosure provides modified immune cells (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen (PSMA) (e.g., human PSMA). The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor. The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor, wherein the modified cell is capable of expressing and secreting a bispecific antibody.

Abstract: The present invention relates to combinations comprising anti-human OX40L antibodies, new biomarkers of autoimmune or alloimmune deseases, and their use in various therapeutic methods.

Abstract: The invention provides methods of treating non-cancerous disorders in a subject by providing the subject with compositions containing hematopoietic cells. In certain embodiments, the compositions include CD34+ cells and CD3+ cells. In certain embodiments, the compositions include CD34+ cells and facilitating cells. The methods are useful for treating blood cell disorders and other disorders that can be ameliorated by providing donor hematopoietic cells.

Abstract: The present invention as described herein is aimed at combining a radiation-induced immunogenic effect with a T-cell therapy technique to markedly improve the therapeutic effectiveness of adoptive T-cell therapy with minimized toxicity. The method of this invention comprises, identifying a target tumor, applying ablative radiation treatment to the tumor in-situ, waiting for the production of CTLs primed by antigen presenting cells (APC), then resecting the target tumor from the patient. The CTLs are harvested and isolated from the tumor and undergo ex-vivo expansion and subsequent treatment of immune checkpoint blockades. The expanded CTLs are then infused back into the patient for systemic treatment of microscopic disease. The primed CTLs that are induced by radiation in-situ, are used as the source of T-cell therapy or other types of cell therapy. The harvested CTLs will have high tumor specificity with a wide range of heterogeneous tumor associated antigens (TAA) presentation.

Abstract: The disclosure relates to the expansion and differentiation of mesenchymal stem cells and bone marrow cells, including retention of stem cell plasticity during expansion and differentiation of stem cells to produce osteocytes, chondrocytes and other cells of the mesodermal lineage.

Abstract: To provide a preservative solution for live cells or a composition containing live cells, a method for preserving live cells or a composition containing live cells by use of the preservative solution and the like, the preservative solution being easy to prepare and exhibiting a high cytoprotective effect, especially during low-temperature storage. The preservative solution for live cells or a composition containing live cells contains vitamin C and/or vitamin E or edaravone in a solution serving as a base of the preservative solution, for example, a physiological isotonic solution.

Abstract: The present invention relates to the preparation of an extract of the crustacean Artemia salina and to the use thereof to treat diseases of the ocular surface. The invention describes the application of the extract mainly by means of soaps, eyedrops, eye solutions, eye washes, aerosols, in the presence of unguents, creams, gels or contact lenses, inter alia. The application of the Artemia salina extract is efficient for treating pathologies consistent with ocular dryness (dry eye) and the manifestations thereof such as the appearance of injuries or ulcers on the ocular surface or infections caused by microorganisms and associated with dry eye, also on of the ocular surface.